Module 2 Class Discussion
1. There are several issues with pegging a currency. Largely they relate to the economic distortion this creates – Chinese good are cheaper than they should be in America and American goods are more expensive than they should be in China. This results in higher employment in China, higher GDP, but also much higher inflation. In the US, inflation is held low but employment and GDP growth are suppressed (Lee, 2017).
2. Liability isn't the same thing as risk. Liability is a form of risk, so I'm not 100% what the question is asking. Yes, pharmaceutical companies are likely to face a substantial amount of liability. Liability risk arises when a company sells anything that is ingested into the body, and pharmaceuticals can be especially powerful. They are a product that, despite being tightly regulated, often has tremendous potential to harm its users, and that alone will create a fair amount of liability risk.
But there are other ways pharmaceutical companies face risk, such as with their marketing. Marketing drugs for off-label uses is prohibited by law, but there are often powerful economic incentives for pharmaceutical companies to do so. Drug companies are often sued for...
References
Fame, E. & French, K. (1989) Business conditions and expected returns on stocks and bonds. Journal of Financial Economics. Vol. 25 (1989) 23-49.
Lee, R. (2017) The pros and cons of a pegged exchange rate. Investopedia. Retrieved August 5, 2017 from http://www.investopedia.com/articles/forex/08/pegged-vs-floating-currencies.asp
MSN Moneycentral (2017) General Electric. MSN Moneycentral. Retrieved August 5, 2017 from http://www.msn.com/en-us/money/stockdetails?symbol=GE&ocid=qbeb
MSN Moneycentral (2017) Target. MSN Moneycentral . Retrieved August 5, 2017 from http://www.msn.com/en-us/money/stockdetails?symbol=TGT&ocid=qbeb
MSN Moneycentral (2017) Wal-Mart MSN Moneycentral . Retrieved August 5, 2017 from http://www.msn.com/en-us/money/stockdetails?symbol=WMT&ocid=qbeb
Stempel, J. (2016) Pfizer in $486 million settlement of Celebrex, Bextra litigation. Reuters. Retrieved August 5, 2017 from http://www.reuters.com/article/us-pfizer-lawsuit-idUSKCN10D1D8
Also cited as threats are those of: (1) Product manufacturing and marketing risks; (2) Cost and expense control or unusual events; and (3) Changes in laws and accounting standards. (Pfizer Inc. Report to the United States Securities and Exchange Commission, 2008) IV. Internal Environment -- Strength and Weaknesses Stated as strengths of Pfizer Inc. are the following components of its organization: (1) Written policies and procedures; (2) a compliance officer and compliance committee; (3) Effective training
Pfizer Inc. - Good Buy in Pharmaceutical Stock? Pfizer Inc., is a giant in the Pharmaceutical Sector. It is traded on the New York Stock Exchange under ticker symbol PFE. Its principle activities include the research and manufacturing of prescription medicines for human and veterinary applications on a global scale. Their products carry such familiar names as Zoloft, Lipitor, Norvasc, Zithromax, Zyrtec, and the household name, Viagra. They also have a
Pfizer's Batch Process Design Model Pfizer is a global pharmaceutical manufacturer heavily invested in drug discovery (Pfizer, 2013a). Accordingly, the supply chain needs of Pfizer are atypical of most manufacturers because a significant portion of its production activities must be tailored to meet the needs of researchers investigating the efficacy of drugs in clinical trials. The needs of the research and development arm of Pfizer therefore dominate the process development structure
Pfizer The Economics of the Pharmaceutical Industry -- Focus on Pfizer Drugs Specify on some background of the company According to its official website, Pfizer Incorporated "discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Our innovative, value-added products improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has
The other considerations weight more heavily. There are likely some cost savings due to economies of scale, although that would be difficult to test for in a product such as Viagra, which has enjoyed strong sales its entire existence, and for which specific production cost data is unavailable. With respect to Viagra, Pfizer is operating in a constant returns to scale environment. The market for Viagra has been slow growing
The return on assets was 7.3% last year, up slightly from 7.1% the year before. Again, the metric has fluctuated and 7.3% is in the middle. These figures indicate that Pfizer's returns are about average. Aside from an unusually good year in 2007 with respect to their returns, the company is rangebound in terms of its managerial efficiency. Recapturing the 2007 successes would be more encouraging but at present there
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now